Table 6.

Considerations for treatment of lymphoma during the COVID-19 pandemic

Lymphoma	Induction treatment	Consolidation and maintenance therapy	R/R patient	Reference
HL	Early stage: Four cycles of ABVD with an interim of PET-CT (favorable disease) Advanced stage: 1. ABVD+PET/CT 2. AAVD+G-CSF	Conventional HL regimens+prophylactic antibiotics	1. Second-line regimens (e.g., gemcitabine-based regimens) 2. Brentuximab vedotin or PD1 antibodies	Advani et al., 2020b; ESMO, 2020b
NHL (mainly focused on DLBCL)	High-risk: 1. CHOP-21 regimens 2. G-CSF to minimize neutropenia Medium-risk: 1. Non-curative treatment could be delayed 2. Avoid T-cell suppressive agents (e.g., bendamustine)	High-risk: Lenalidomide+RTX (R2) or lenalidomide+corticosteroids Others: 6-MP+MTX	1. High-dose chemotherapy+ASCT 2. Second-line chemotherapy 3. Lenalidomide-based therapy 4. Polatuzamab+bendamustine 5. CAR-T cell therapy	Advani et al., 2020a; ESMO, 2020a

AAVD, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ASCT, autologous stem cell transplantation; CAR-T, chimeric antigen receptor T cell; CHOP-21, three-weekly cyclophosphamide, doxorubicin, vincristine, and prednisolone; COVID-19, coronavirus disease 2019; DLBCL, diffuse large B-cell lymphoma; G-CSF, granulocyte-colony stimulating factor; HL, Hodgkin lymphoma; 6-MP, 6-mercapto-purine; MTX, methotrexate; NHL, non-Hodgkin lymphoma; PD1, programmed cell death protein 1; PET/CT, positron emission tomography/computed tomography; R/R, relapsed or refractory; RTX, rituximab